Monrol and FutureChem Announced a Clinical Supply Partnership
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply of radioisotope, Lu-177 n.c.a. (Lutetium-177 non-carrier-added), to support FutureChem’s Investigational New Drug IND-enabling Phase 2 clinical trial with Ludotadipep, 177Lu-FC705 to assess the efficacy and safety for repeated administration of the recommended Ludotadipep dose in patients with metastatic castration resistant prostate cancer (mCRPC). Clinical supply contract signed by two parties on 18th of Oct 2022 in Barcelona. A new supply contract between Monrol and FutureChem will be signed following the commercialization of the product in South Korea and US.
Monrol General Manager Aydın Küçük,added: “We are delighted to be working with FutureChem to have a clinical supply agreement to support clinical development program of an innovative radiopharmaceutical product Ludotadipep, 177Lu-FC705 to assess the efficacy and safety in patients with metastatic castration resistant prostate cancer (mCRPC). Collaboration with FutureChem is another example of we continue our mission to improve quality of life for cancer patients and transform patient care for the future.”
Dae Yoon Chi, Chief Executive Officer, FutureChem said: “FutureChem is thrilled to be partnering with Monrol, a company with a broad set of offerings to support our development programs and pipeline. We look forward to rolling out the supply of high-quality radioisotopes to our Phase 2a clinical trial patients in US soon. We have a future prospect to expand this partnership, supply of radioisotope, Lu-177 n.c.a. by Monrol for the commercialization of the Ludotadipep, 177Lu-FC705”.
ENDS
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About FutureChem
Since its establishment in 1999, FutureChem has led the radiopharmaceuticals industry through research and development. FutureChem is the global forerunner in the production of radiopharmaceutical precursors and compounds, development of remarkable radiopharmaceuticals, and worldwide commercialization of new medicine.
FutureChem developed competitive technologies and innovative products with a mission to grow the company into a world-class radiopharmaceuticals enterprise, so to contribute a healthy and happy society, protecting the health of patients.
For more information, please visit www.futurechem.co.kr
About FC705 and 177Lu-FC705
2nd generation PSMA-targeted therapeutic radiopharmaceuticals. 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding. 177Lu-FC705 will have constantly increasing uptake in prostate cancer due to the introduction of albumin binder while it will be rapidly excreted from normal organs. In this regard, 177Lu labeled 177Lu-FC705 can be expected to have high therapeutic effect and very low damage to normal organs. Currently, efficacy of 177Lu-FC705 is being clinically tested in Phase 2 in Korea and 1/2a in US.
About n.c.a. Lutetium-177
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today and more potential treatment options in future under clinical development. The unique properties of Lu-177 n.c.a. make it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. N.c.a. Lutetium-177 DMF by Monrol listed by FDA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005260/en/
Contact information
For further information please contact:
Monrol
Aydın Küçük
General Manager
monrol@monrol.com
FutureChem
Dae Yoon Chi
CEO
daeyoon.chi@futurechem.co.kr
Media Enquiries
Alkim Aydın
Email: alkim.aydin@monrol.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dataocean AI Unveils NEW Brand, NEW Site, and NEW Multilingual Speech Corpus for Speech Foundation Models at ICASSP 202416.4.2024 07:00:00 CEST | Press release
Dataocean AI, a global data services provider, is pleased to announce a NEW brand, a NEW site, and a NEW Multilingual Speech Corpus for Speech Foundation Models at ICASSP 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415891226/en/ Dataocean AI's New Website (Graphic: Business Wire) Dataocean AI announced the upgrade of its branding at ICASSP. The new brand, characterized by dynamic gradient design, symbolizes the company's unwavering commitment to excellence and innovation in the AI data industry. With almost 20 years of experience in the AI data industry, Dataocean AI will continue to innovate, subvert the industry with technology, and provide cost-effective data products and services for over 900 enterprises and research institutes globally. Meanwhile, Dataocean AI launched the new site. A key highlight of the new site is that they have created an e-commerce model for shopping datasets, making it more accessible
GridBeyond Closes €52M Series C Funding Round to Continue Its Platform Evolution and Invest in New & Existing Markets16.4.2024 06:00:00 CEST | Press release
GridBeyond, the leading intelligent energy and smart grid platform provider for distributed energy resource management, has closed its €52M Series C financing round. The round was led by Alantra’s Energy Transition Fund, Klima. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415760197/en/ GridBeyond closes €52M Series C funding round to continue its platform evolution and invest in new & existing markets. (Graphic: Business Wire) The Series C round also included new investors Energy Impact Partners, Mirova, ABB, Constellation and Yokogawa Electric Corporation as well as investment from existing investor, Act Venture Capital. Since its foundation in 2010, GridBeyond has been developing its AI platform to help businesses unlock the full potential of energy assets, ensuring the sustainability, resilience, and affordability of energy as the world moves towards a zero-carbon future. GridBeyond’s technology unleashes the latent
World Famous Soccer Star Neymar Junior Joins Forces With Fun Brands and Enters the Cocktails and Mocktails Business With His Own Brand15.4.2024 18:00:00 CEST | Press release
Neymar da Silva Santos Júnior, known as one of the best soccer players in the world, joins forces with Fun Brands, a Miami, Florida-based beverage company, to announce a new collaborative venture of innovative, all-natural spirit- and wine-based cocktails and zero alcohol mocktails launching in Brazil later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415201897/en/ World Famous Soccer Star Neymar Junior Announces Collaborative Venture With Fun Brands to Enter Cocktail and Mocktail Business With Own Brand (Photo: Business Wire) “This is a great opportunity for me to celebrate in a new way with my fans worldwide, creating possibilities for connection beyond soccer, which is my life,” highlighted the All-star. “I want to share the flavors of Brazil that I love the most with my soccer fans at home and around the world in a different and irreverent way. The idea of also offering non-alcoholic beverages greatly att
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome15.4.2024 15:15:00 CEST | Press release
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL). CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs. In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab
Brightcove Introduces Smart TV SDKs for Roku, Samsung, and LG Devices, Empowering Media Companies to Reach New Audiences15.4.2024 15:00:00 CEST | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced the launch of its new player platforms for Roku, Samsung and LG Smart TVs. The launch of the new Software Development Kits (SDKs) has unlocked advanced features within Brightcove’s industry-leading player framework, including content protection, monetization, and analytics reporting capabilities. Designed to reduce the cost and speed of high-quality app development, media companies can more effectively target the Smart TV platforms fueling media growth while delivering a consistent, engaging premium viewer experience. “Brightcove is committed to helping media companies deliver engaging and world-class reliable streaming experiences while reducing the costs traditionally associated with launching and running an OTT service," said Scott Levine, Chief Product Officer at Brightcove. “Our comprehensive platform enables media companies to benefit from out-of-the-box functionality and deliver pre